Abstracts

New ARVs Could Represent More Than USD 3 Billion in Cost Savings Through 2025

Several new antiretrovirals (ARVs) are likely to be introduced in low-and middle-income countries (LMICs) by 2019 that represent a range of clinical and cost advantages to current products. These include tenofovir alafenamide fumarate (TAF), low dose efavirenz (EFV400), and dolutegravir (DTG). As programs evaluate adoption of these products, it is important that they understand the…

Malawi’s Option B+ 2011-2015: The Impact of Rapid ART Decentralization

In July 2011, Malawi began offering lifelong ART to all HIV-infected pregnant and breastfeeding women, regardless of clinical or immunological stage (Option B+). To scale up this policy, Malawi fully integrated PMTCT and ART services and decentralized services to all facilities. Critical enablers included highly simplified and standardized clinical guidelines aiming to eliminate barriers to…

Optimizing PMTCT Outcomes in Rural North-Central Nigeria: A Cluster-Randomized Study

Antiretroviral therapy (ART) and retention in care are essential for prevention of mother-to-child HIV transmission (PMTCT). In a randomized trial, we assessed the impact of a family-focused, integrated PMTCT care package on maternal ART initiation, post-partum mother-infant pair retention and infant HIV infection. We pair-matched 12 sites, randomizing clinic-pairs to intervention vs. control (SOC) arms.…

Randomized Trial of a Lay Counselor-Led Combination Intervention for PMTCT Retention

Despite simplification of prevention of mother-to-transmission (PMTCT) services, retention of HIV positive (HIV+) mothers and infants across the PMTCT-pediatric care continuum remains problematic. A variety of interventions have been proposed to improve retention but rigorous assessment of their efficacy to improve maternal and child outcomes are scarce. The Maternal-Infant Retention for Health (MIR4Health) study was…